Sarepta Therapeutics (NASDAQ:SRPT) Upgraded by HC Wainwright to "Neutral" Rating

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) was upgraded by research analysts at HC Wainwright from a "sell" rating to a "neutral" rating in a research report issued on Wednesday, MarketBeat Ratings reports. The brokerage presently has a $75.00 price target on the biotechnology company's stock. HC Wainwright's price target indicates a potential upside of 46.68% from the company's previous close.

A number of other brokerages have also recently weighed in on SRPT. Scotiabank reduced their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a report on Thursday, March 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $163.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and cut their price target for the company from $161.00 to $87.00 in a report on Monday, March 31st. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. Six investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $163.18.

Remove Ads

Sarepta Therapeutics Trading Down 6.1 %

SRPT stock traded down $3.30 on Wednesday, hitting $51.13. 1,194,289 shares of the company were exchanged, compared to its average volume of 1,324,581. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock has a market capitalization of $4.96 billion, a price-to-earnings ratio of 40.94 and a beta of 0.93. Sarepta Therapeutics has a twelve month low of $50.55 and a twelve month high of $173.25. The business's fifty day moving average is $96.95 and its two-hundred day moving average is $113.62.

Insider Activity

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 7.70% of the company's stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quantbot Technologies LP acquired a new position in shares of Sarepta Therapeutics during the third quarter valued at $237,000. Captrust Financial Advisors lifted its stake in shares of Sarepta Therapeutics by 15.2% in the 3rd quarter. Captrust Financial Advisors now owns 3,871 shares of the biotechnology company's stock worth $483,000 after acquiring an additional 511 shares during the period. Stifel Financial Corp boosted its holdings in shares of Sarepta Therapeutics by 99.3% in the third quarter. Stifel Financial Corp now owns 37,207 shares of the biotechnology company's stock valued at $4,647,000 after acquiring an additional 18,537 shares in the last quarter. Soros Fund Management LLC bought a new position in shares of Sarepta Therapeutics in the third quarter valued at approximately $25,800,000. Finally, Wellington Management Group LLP increased its stake in shares of Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock valued at $340,527,000 after acquiring an additional 665,087 shares during the period. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.